Azitra, Inc. (AZTR) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing novel therapeutics for precision dermatology using genetically engineered microbes. The company operates as a single segment and is currently in the pre-commercialization phase with no product revenue. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Total Revenue | $0 | $0 | $7,500 |
| Net Loss | $(2,764,528) | $(8,721,866) | $(6,574,359) |
| Operating Expenses | $2,768,484 | $8,740,074 | $8,558,484 |
| Cash and Equivalents (End of Period) | $1,401,878 | N/A | |
| Working Capital | $423,942 | N/A | |
| Accumulated Deficit | $(66,287,692) | N/A |
Liquidity & Debt: As of September 30, 2025, the company held approximately $1.4 million in cash. Total liabilities were $2.0 million, primarily consisting of accounts payable ($718k), accrued expenses ($507k), and lease liabilities. The company has an Equity Line of Credit (ELOC) with Alumni Capital LP for up to $20 million; approximately $6.0 million in gross proceeds were received under this facility through November 2025, with $14.0 million remaining available.
Material Changes vs. Prior Period
- Net Loss Increase: The net loss for the nine months ended September 30, 2025, increased by 33% to $8.7 million compared to $6.6 million in the prior year period. This increase is primarily due to higher operating expenses and the absence of a $4.0 million non-cash gain from the change in fair value of warrants recorded in the prior year.
- Operating Expenses: Total operating expenses increased slightly by 2% year-over-year. Research and Development (R&D) expenses rose 6% to $3.8 million, driven by clinical trial progression for programs ATR-04 and ATR-01. General and Administrative (G&A) expenses decreased 1% to $4.9 million, largely due to reduced legal fees and stock-based compensation, partially offset by increased accounting and public relations costs.
- Other Income: Total other income decreased by 99% year-over-year, dropping from $2.0 million to $18k. This was driven by the absence of the $4.0 million warrant valuation gain and the $2.1 million loss on issuance of common stock recorded in 2024.
- Capital Structure: The company completed follow-on offerings in January and February 2025 and began utilizing its ELOC in April 2025. A 6.66-for-1 reverse stock split was effected in August 2025.
Outlook, Risks, and Management Commentary
- Going Concern: Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern for twelve months from the filing date. The company has an accumulated deficit of $66.3 million and expects to incur significant losses as it advances clinical trials. Additional financing is required to fund operations.
- Listing Compliance: On October 1, 2025, the company received a deficiency letter from NYSE American regarding non-compliance with stockholders' equity requirements (minimum $4.0 million). The company reported equity of $2.2 million as of June 30, 2025. A compliance plan was submitted to regain compliance by April 1, 2027. Failure to comply could result in delisting.
- Internal Controls: Management identified a material weakness in disclosure controls and procedures related to a lack of adequate segregation of accounting functions. Plans are in place to increase accounting staffing to remediate this.
- Clinical Progress: The company reported initial safety results for ATR-12 (Netherton syndrome) in the first half of 2025 and dosed the first patient in the ATR-04 (EGFRi rash) Phase 1/2 trial in Q3 2025.
- Risks: Key risks include the inability to secure additional financing, potential delisting from NYSE American, trade policy changes affecting foreign manufacturers, and the inherent risks of clinical development.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.4 million cash balance against the projected burn rate and the timeline for securing additional capital.
- ELOC Utilization: Confirm the terms and remaining capacity of the $20 million Equity Line of Credit with Alumni Capital LP and the dilution impact of associated warrants.
- Listing Status: Monitor the status of the NYSE American compliance plan and the company's ability to meet the $4.0 million equity requirement by April 2027.
- Internal Controls: Assess the progress of remediation efforts regarding the material weakness in segregation of accounting duties.
- Clinical Milestones: Track upcoming data readouts for ATR-12 and ATR-04, as these are critical for future valuation and funding opportunities.